Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cetrorelix trifluoroacetate
Drug ID BADD_D00421
Description Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur.
Indications and Usage For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
Marketing Status approved; investigational
ATC Code H01CC02
DrugBank ID DB00050
KEGG ID D07665; D01685
MeSH ID C062876
PubChem ID 25074886
TTD Drug ID D09OLZ
NDC Product Code 41524-0013; 78848-005
UNII 26089221C6
Synonyms cetrorelix | N-acetyl-1-(3-(2-naphthyl)alanine)-2-(4-chlorophenylalanine)-3-(3-(3-pyridyl)alanine)-6-citrulline-10-alanine-LHRH | LHRH, N-Ac-1-Nal(2)-2-Phe(pCl)-3-Pal(3)-6-Cit-10-Ala- | LHRH, N-acetyl-1-(3-(2-naphthyl)alanyl)-2-(4-chlorophenylalanyl)-3-(3-(3-pyridyl)alanyl)-6-citrulline-10-alanine- | SB 75 | SB-75 | Cetrotide | cetrorelix acetate | cetrorelix pamoate
Chemical Information
Molecular Formula C72H93ClF3N17O16
CAS Registry Number 130289-71-3
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCNC(=O)N)NC(=O )C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CN=CC=C3)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(= O)C(CC5=CC6=CC=CC=C6C=C5)NC(=O)C.C(=O)(C(F)(F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Anencephaly17.19.03.001; 03.10.03.001--Not Available
Assisted fertilisation25.10.04.001--Not Available
Congenital anomaly03.02.01.001--Not Available
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Developmental glaucoma06.03.02.001; 03.01.05.001--Not Available
Diaphragmatic hernia07.16.01.002; 22.09.02.001--Not Available
Erythema23.03.06.001--Not Available
Glaucoma06.03.01.002--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Imperforate hymen21.08.01.004; 03.03.04.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Klinefelter's syndrome03.20.05.001; 05.05.02.005--Not Available
Local reaction08.01.03.012--Not Available
Melanocytic naevus23.10.01.007; 16.26.01.007--Not Available
Nausea07.01.07.001--
Ovarian hyperstimulation syndrome21.11.02.007; 05.05.01.013--Not Available
Pruritus23.03.12.001--
Stillbirth18.01.02.002; 08.04.01.006--Not Available
Supernumerary nipple21.05.04.020; 03.03.03.001--Not Available
Swelling08.01.03.015--Not Available
Trisomy 2103.20.01.002; 19.21.06.005; 17.03.07.005; 02.08.02.003--Not Available
Ventricular septal defect03.07.02.001; 02.04.02.007--Not Available
Contusion12.01.06.001; 15.03.05.007; 24.07.06.001; 23.03.11.002--
Trisomy 1817.03.07.004; 02.08.01.003; 03.20.01.001; 19.21.06.004--Not Available
The 1th Page    1    Total 1 Pages